Navigation Links
EUPROBIO 2008 Presentation to Highlight Latest Immune Research
Date:10/6/2008

Presentation to focus on a new dietary supplement resulting from years of study by leading research scientists in Russia, Ukraine and Bulgaria,

Del-Immune V

BOULDER, Colo., Oct. 6 /PRNewswire/ -- On Thursday, October 16, 2008 at the EUPROBIO 2008 Conference, an abstract entitled "Immune regulatory cytokines Del-Immune V(R) induction and its impact on cytotoxicity of natural killer cells" will be presented to physicians, researchers and educators. Attendees to the presentation will learn about the latest advancements in this field of research. After seeing the study abstract, conference organizers made last-minute changes to the conference schedule to include a presentation of this groundbreaking research.

The abstract is based on a recent study focusing on Del-Immune V(R), a new immunomodulator containing DNA and peptoglycan fragments of lactobacillus rhamnosus V. The study, which confirms that this formulation enhances immune function, was conducted in the Ukraine by several of Europe's foremost research scientists.

Among other findings, the study demonstrated that daily administration of Del-Immune V(R) within 5 days raised a level of circulating interferon up to 4.2+/-0.5 log2 u/ml (P <0.05) against 2.0+/-0.3 log2 u/ml of the controls. Interferons are the switches that help cells resist viral infection and provide the initial, crucial immune response to immune challenges. The results of this latest research demonstrate the immune modulator activity of Del-Immune V(R) and the potential value the dietary supplement may have in clinical situations.

Del-Immune V(R) is a dietary supplement containing a natural culture that starts with healthy bacteria originally found in unpasteurized milk. Unique technological processing of the Del-Immune V(R) formulation creates a natural immunostimulant. The study described above and other research indicates that Del-Immune V(R) could be beneficial in assisting th
'/>"/>

SOURCE Pure Research Products, LLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Strategic Diagnostics Updates Roth Conference Presentation Time
2. Caliper Life Sciences Presentation at Thomas Weisel Partners Healthcare Conference to be Webcast
3. Thomas Weisel Partners 2007 Healthcare Conference To Webcast Millennium Presentation
4. deCODE genetics to Webcast Presentation at Thomas Weisel Partners Annual Healthcare Conference
5. FDA and Conformia Deliver Joint Presentation to Annual Regulatory and Compliance Symposium at Harvard
6. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Partners Conference
7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BioCentury-Thomson Financial Investment Conference
8. Volcano Corporation Presentation at Bear Stearns Conference to be Webcast
9. Telik Announces Presentation and Webcast at Bear Stearns Healthcare Conference
10. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
11. ZymoGenetics to Webcast Presentation at Two Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Freeslate, Inc ., the leading ... Lupin Limited, one of India’s top five pharmaceutical companies, ... System for high throughput solid form screening. ... a wide range of quality, affordable generic and branded ...
(Date:1/14/2014)... 14, 2014 Histogen, Inc., a regenerative ... cells grown under simulated embryonic conditions, today announced that ... Suneva Medical, Inc. for physician-dispensed aesthetic products containing Histogen’s ... This agreement is an amendment to the existing license ...
(Date:1/14/2014)... SAN DIEGO and BETHESDA, Md. ... they are joining together with two institutes from the ... more reliable tools for bringing safer, more effective treatments ... with the National Center for Advancing Translational Sciences (NCATS) ...
(Date:1/14/2014)...   Kinaxis ®, provider of RapidResponse ®, a cloud-based ... planning ( S&OP ) service, is proud to be a ... be held at the Hilton San Diego Bayfront, January 30 ... Elisabeth Kaszas , Director of Supply Chain at Amgen, as ...
Breaking Biology Technology:Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... Dr. Pollard Brings the Highest Level of Clinical ... Feb. 1 Genetic,Immunity(R), a US/Hungarian clinical-stage biopharmaceutical ... patented,immunotherapeutic platform technology, announced that it has appointed,Richard ... Dr. Pollard has been a leader in HIV/AIDS ...
... N.J., Feb. 1 Amicus Therapeutics,Inc. (Nasdaq: FOLD ... Executive Officer, will present a corporate update at the ... York, NY on Thursday, February 7, 2008 at 11:40 ... The presentation will be webcast live and may be ...
... 31 Rigel,Pharmaceuticals, Inc. (Nasdaq: RIGL ) today ... of common stock at a price of $27.00,per share. ... The underwriters,have an option to purchase up to an ... is expected to close on February 6,2008, subject to ...
Cached Biology Technology:Genetic Immunity Announces the Appointment of Richard B. Pollard, M.D. as Chief Medical Officer 2Genetic Immunity Announces the Appointment of Richard B. Pollard, M.D. as Chief Medical Officer 3Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference 2Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference 3Rigel Announces Pricing of Public Offering of Common Stock 2
(Date:4/17/2014)... Razzari of the nergie Matriaux Tlcommunications Research Centre ... John R. Evans Leaders Fund of the Canada ... state-of-the-art biotech and nanophotonics equipment. To this funding ... de l,Enseignement suprieur, de la Recherche, de la ... laboratories will help us develop new approaches for ...
(Date:4/17/2014)... University engineer has developed a patented technique that ... devices. The same technique could help police during ... and Kay L. Theede chair in engineering and ... his research team have created a template-based system ... trunks. The distance detection method called stand-off ...
(Date:4/17/2014)... is available in German . ... the protection money demanded of him, he can expect his ... however, as fear of the consequences is enough to make ... parasitic birds, which lay their eggs in other birds, nests. ... brood parasites take their revenge by destroying the entire nest. ...
Breaking Biology News(10 mins):New state-of-the-art biotech and nanotech equipment for INRS 2Patented research remotely detects nitrogen-rich explosives 2Fear of the cuckoo mafia 2Fear of the cuckoo mafia 3
... PHILADELPHIA -- Scientists are another step closer to ... there are factors inside tumors that can slow their ... Cancer Research , a journal of the American Association ... researcher at the division of experimental medicine at the ...
... A recent study led by researchers at Boston University School ... mortality among patients diagnosed with severe sepsis and new-onset atrial ... assistant professor of medicine at BUSM and a pulmonologist at ... study, which will be published in the Journal of the ...
... SAN FRANCISCO Combining the investigational agents REGN910 ... effects in animal models compared with either agent ... International Conference: Molecular Targets and Cancer Therapeutics, held ... findings suggest that combining REGN910 (SAR307746) and aflibercept ...
Cached Biology News:BUSM: Severe sepsis, new-onset AF associated with increased risk of hospital stroke, death 2Combination therapy shows potent tumor growth inhibition in preclinical studies 2
a1-Antitrypsin (human, alpha-1 AT)...
... vesicles are used to study co-translational ... Processing events such as signal peptide ... glycosylation can be examined by the ... vitro in the presence of these ...
... using Mo Bio luciferase assay. Mo Bio Laboratories ... will allow you to certify your products ATP-Free ... you to deliver them to your customers in ... limit is 3.5 x 10-12 /l, which will ...
... New Concept in Microarrays: Biomedical Photometrics Inc. ... GmbH (Jena, Germany) have collaborated to develop ... ArrayTube System. The DNAscope AT is ... new DNAscope AT automatically reads up to ...
Biology Products: